Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


White House CAM commission

This article was originally published in The Tan Sheet

Executive Summary

Town Hall meeting scheduled for Sept. 8 in San Francisco to hear "testimony from individuals and organizations interested in the subject of federal policy regarding complementary and alternative medicine," an Aug. 22 Federal Register notice announces. Comments should focus on four areas: coordinated R&D of CAM practices; access to, delivery of and reimbursement for CAM services; training, education and licensing; and delivery of CAM information to health care professionals and the public. Future town hall meetings are anticipated at other locations. The commission's findings are due in March 2002 (1"The Tan Sheet" July 17, p. 16)

You may also be interested in...

White House Commission On CAM Presented Queries From Harkin

Senator Tom Harkin (D-Iowa) posed several questions to the White House Commission on Complementary & Alternative Medicine at their commencement meeting in Washington, D.C. July 13.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts